Identification of patients best suited for combined liver-kidney transplantation: Part II

Liver Transplantation

Volumn 8, Issue 3, 2002, Pages 193-211

  Davis, Connie L ^a   Gonwa, Thomas A ^b   Wilkinson, Alan H ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR;

ACUTE KIDNEY FAILURE; ALGORITHM; CONTROLLED STUDY; DIALYSIS; DISEASE COURSE; GRAFT REJECTION; HEALING; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECIPIENT; REVIEW; SURVIVAL;

EID: 0036201160     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.32504     Document Type: Article

References (112)

1. Liver transplantation and renal function: Results in patients with and without hepatorenal syndrome
2. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation
3. Recovery from "hepatorenal syndrome" after orthotopic liver transplantation
4. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome
5. Spontaneous recovery from the hepatorenal syndrome
6. Renal replacement therapy (RRT) and orthotopic liver transplantation (OLTX): The role of continuous veno-venous hemodialysis (CVVHD)
7. Risk factors for acute renal failure requiring dialysis after liver transplantation
8. Impact of pre-transplant renal function on survival after liver transplantation
9. Late-onset renal failure after liver transplantation: Role of posttransplant alcohol use
10. Acute and chronic renal failure in liver transplantation
11. Hepatorenal syndrome: Combined liver kidney transplants versus isolated liver transplant
12. Effects of renal impairment on liver transplantation
13. The hepatorenal syndrome in liver transplant recipients
14. Determinants of renal failure in patients receiving orthotopic liver transplants
15. Posttransplant dialysis associated morbidity and impact on outcome in liver transplant recipients
16. Factors affecting survival after livingrelated liver transplantation
17. Outcome of liver transplantation in critically ill patients with alcoholic cirrhosis: Survival according to medical variables and sobriety
18. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation
19. Orthotopic liver transplantation in high risk patients: Risk factors associated with mortality and infectious morbidity
20. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation
21. Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation
22. Renal failure in fulminant hepatic failure and terminal cirrhosis: A comparison between incidence, types, and prognosis
23. Renal outcomes in pediatric liver transplantation
24. Infectious complications in liver recipients on tacrolimus: Prospective analysis of 88 consecutive liver transplants
25. Invasive aspergillosis in liver transplant recipients in the 1990's
26. Clinical monitoring of intracranial pressure in fulminant hepatic failure
27. Brain lactate by magnetic resonance spectroscopy during fulminant hepatic failure in the dog
28. Electron microscopic study of brain capillaries in cerebral edema from fulminant hepatic failure
29. Is there a role for continuous renal replacement therapies in patients with liver and renal failure?
30. Renal replacement therapy in the patient with acute brain injury
31. Cerebral oedema and increased intracranial pressure in chronic liver disease
32. Dialysis, hemofiltration, and other extracorporeal techniques in the treatment of the renal complications of liver disease
33. Molecular adsorbent recycling system (MARS): Clinical results of a new membrane-based blood purification system for bioartificial liver support
34. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial
35. Continuous venovenous hemodialysis treatment in critically ill patients after liver transplantation
36. Renal disease in hepatitis C-positive liver transplant recipients
37. End stage renal disease (ESRD) following orthotopic liver transplantation (OLTX) utilizing calcineurin based immunotherapy: Risk of development and treatment
38. Chronic renal failure following liver transplantation. A retrospective analysis
39. The clinical impact of nephrotoxicity in liver transplantation
40. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil
41. Combined liver and kidney transplantation in patients with chronic nephritis associated with end-stage liver disease
42. Combined liver and kidney transplantation
43. Successful combined kidney-liver right lobe transplant from a living donor
44. Combined liver-kidney transplantation from a living related donor
45. Single center experience of combined liver and kidney transplantation
46. Combined liver-kidney transplantation in patients with cirrhosis and renal failure: Effect of a positive cross-match and benefits of combined transplantation
47. Experience in one center of combined kidney and liver transplantation in 22 patients: Incidence of graft rejection and long-term graft outcome
48. Long-term results of combined kidney and liver transplantation at one center
49. Long-term outcome of 27 patients after combined liver-kidney transplantation
50. Combined liver-kidney transplantation: Long-term follow up in 18 patients
51. Combined liver-kidney transplantation and the effect of preformed lymphocytotoxic antibodies
52. Combined liver-kidney transplantation: Analysis of patients with preformed lymphocytotoxic antibodies
53. Preliminary results with combined hepatorenal allografting
54. Combined liver-kidney transplantation
55. The role of combined liver/kidney transplantation in end-stage hepato-renal disease
56. Combined liver kidney transplantation: What are the indications?
57. Liver and kidney transplantation for polycystic disease
58. Long-term results of combined kidney and liver transplantation in patients with nephropathy associated with liver disease
59. Combined liver-kidney transplantation: Our experience
60. Combined liver and kidney transplantation against a positive cross match in a patient with multispecific HLA-antibodies
61. Oxalosis registry report 1987-1999
62. Combined liver and kidney transplantation in children
63. Liver transplantation, 1990: A Dallas perspective
64. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival
65. Transplantation for primary hyperoxaluria in the United States
66. The results of combined liver/kidney transplantation for primary hyperoxaluria (PH1) 1984-1997. The European PH1 transplant registry report
67. What is new in primary hyperoxaluria?
68. Combined liver-kidney transplantation in primary hyperoxaluria type 1
69. Effects of amlodipine on tubulointerstitial lesions in normotensive hyperoxaluric rats
70. Clinical expression and long-term outcomes of primary hyperoxaluria types 1 and 2
71. Selection of transplantation procedures and perioperative management in primary hyperoxaluria type 1
72. Liver transplantation in metabolic disorders
73. Liver transplantation for polycystic liver disease
74. Liver transplantation for adult polycystic liver disease
75. Liver transplantation for adult polycystic liver disease
76. Massive hepatomegaly in adult polycystic liver disease
77. Renal cystic diseases
78. Liver transplantation (LTx) for polycystic liver disease (PLD)
79. Mortality and frequency in combined liver kidney transplantation
80. The liver neither protects the kidney from rejection nor improves kidney graft survival after combined liver and kidney transplantation from the same donor
81. Significance of a T-lymphocyte crossmatch in liver and combined liver-kidney transplantation
82. Soluble HLA antigens in the circulation of liver graft recipients
83. Microchimerism and rejection in clinical transplantation
84. Peripheral blood chimerism following human liver transplantation
85. Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: With particular reference to chronic rejection
86. Hepatorenal syndrome
87. Assessment of renal function
88. The hepatorenal syndrome
89. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites
90. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems
91. Transjugular intrahepatic portosystemic shunts (TIPS): A decade later
92. Acute renal failure in critically ill patients: Prognosis for recovery of kidney function after prolonged dialysis support
93. Comparison of cellulose diacetate and polysulfone membranes in the outcome of acute renal failure. A prospective randomized study
94. Prognosis of patients with acute renal failure requiring dialysis: Results of a multicenter study
95. PAH extraction and estimation of plasma flow in human postischemic acute renal failure
96. The role of C-reactive protein in graft dysfunction after renal transplantation
97. Risk factors for delayed graft function in cadaveric kidney transplantation: A prospective study of renal function and graft survival after preservation with University of Wisconsin solution in multi-organ donors
98. Delayed graft function influences renal function, but not survival
99. Posttransplantation acute tubular necrosis: Risk factors and implications for graft survival
100. Effect of histological damage on long-term kidney transplant outcome
101. Results of combined liver/kidney transplantation
102. Recurrent and de novo glomerular disease after renal transplantation: A report from Renal Allograft Disease Registry (RADR)
103. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients
104. Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients
105. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients
106. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys
107. The indispensability of heme oxygenase-1 in protecting against acute heme protein-induced toxicity in vivo
108. Simultaneous liver and renal transplantation in man
109. Successful combined liver and kidney transplantation in children despite HLA mismatching